Big Pharma Faces Threat as US-EU Tariff Dispute Puts Best-Selling Drugs at Risk

The pharmaceutical industry is on high alert as the ongoing US-EU tariff spat could potentially target best-selling drugs, raising concerns about increased prices and reduced patient access. Drugmakers are urgently urging U.S. officials and European Union representatives to exclude medical goods from any expanding tariffs, fearing that such measures could lead to significant price spikes for key medications, including Novo Nordisk's Wegovy for weight loss and Merck's Keytruda for cancer treatment.

Pharmaceutical executives have conveyed to U.S. officials that imposing tariffs on European goods would not only elevate drug costs but also create barriers for patients seeking access to critical treatments. This could undermine the objectives outlined in President Trump's health-related executive orders aimed at lowering drug prices and enhancing public health outcomes.

Some companies are signaling a willingness to expand their manufacturing capabilities in the United States, contingent on securing tax breaks and regulatory support to facilitate this transition. A senior executive from a European drugmaker emphasized that "patients will pay the price" if tariffs are implemented, highlighting the interconnected nature of supply chains in the pharmaceutical sector.

Historically, drugs have been exempt from trade disputes due to their essential nature. However, with the Trump administration's previous moves to increase tariffs on imports from China, including raw materials and finished pharmaceuticals, there is growing concern that medicines could soon become part of this trade conflict. The U.S. heavily relies on pharmaceuticals produced in Europe, which generate substantial revenue.

For instance, Novo Nordisk partially produces the active ingredients for Wegovy in Denmark, while Merck manufactures Keytruda in Ireland. The potential for tariffs on these products poses a significant risk to both companies and patients.

As the situation unfolds, pharmaceutical companies are urging the EU to refrain from retaliatory tariffs even if the U.S. proceeds with imposing duties on medicines. Industry leaders warn that disrupting the flow of these essential goods would harm patient access to lifesaving treatments, creating a lose-lose scenario.

With many drugmakers already grappling with rising costs and supply chain challenges, the looming threat of tariffs adds another layer of complexity to an already volatile landscape. As companies navigate these uncertain waters, the repercussions for both the industry and patients remain to be seen.